The prevalence of primary hyperaldosteronism among general and resistant hypertensive populations ranges from 5-20%.  It is considered a secondary form of hypertension caused by inappropriate secretion of aldosterone and activation of the mineralocorticoid receptor.  As such, it is a highly treatable and potentially curable form of hypertension.  This webinar will review the prevalence, pathophysiology, screening and diagnostic studies, and treatment options for patients with primary hyperaldosteronism so that the Practitioner can accurately screen and identify cases.

Learning objectives:

1.  Understand the prevalence, pathophysiology and diagnostic studies for patients with primary hyperaldosteronism.
 
2.  Be able to identify screening and treatment options for patients with primary hyperaldoseronism.